A MULTICENTER OPEN-LABEL, UNCONTROLLED STUDY TO EVALUATE THE PHARMACOKINETICS, PHARMACODYNAMICS, SAFETY, TOLERABILITY, AND ACTIVITY OF ZILUCOPLAN IN PEDIATRIC STUDY PARTICIPANTS FROM 2 TO LESS THAN 18 YEARS OF AGE WITH ACETYLCHOLINE RECEPTOR ANTIBODY POSITIVE GENERALIZED MYASTHENIA GRAVIS

Generalized Myasthenia Gravis

• Plasma concentrations of zilucoplan (ZLP) sampled at Week 4 (Day 29) • Change from Baseline in sheep red blood cell (sRBC) lysis at Week 4 (Day 29) • Change from Baseline in complement component 5 (C5) levels at Week 4 (Day 29)

• Occurrence of treatment-emergent adverse events (TEAEs) during the course of the study, • Occurrence of treatment-emergent serious adverse events (TESAE)s, • Occurrence of TEAEs leading to permanent withdrawal of investigational medicinal product (IMP), • Occurrence of treatment-emergent infections, • Occurrence of antidrug antibody (ADA) and anti- polyethylene glycol (PEG) antibodies at Week 4 (Day 29)., • Change in MG-activities of daily living (MG-ADL) score from Baseline to Week 4 (Day 29)., • Change in Quantitative MG (QMG) score from Baseline to Week 4 (Day 29)., • Myasthenia Gravis Foundation of America Post-Interventional Status (MGFA PIS) at Week 4 (Day 29)., • Change in Pediatric Quality of Life Inventory (PedsQoL), Version 4 domain scores from Baseline to Week 4 (Day 29).

No related papers found yet.

Italy, Poland